Can i switch from mounjaro to zepbound?

Why are some people switching from Mounjaro to Zepbound?

Some individuals are considering switching from Mounjaro (tirzepatide) to Zepbound (dasiglucagon) due to various reasons. However, it's essential to consult with a healthcare provider before making any changes to your treatment plan [1].

How does Zepbound compare with Mounjaro?

Zepbound, a glucagon/GLP-1 receptor agonist, is used for the treatment of type 2 diabetes, while Mounjaro, a dual GIP/GLP-1 receptor agonist, is used for the treatment of type 2 diabetes and obesity [2]. The primary concern when switching from Mounjaro to Zepbound is the potential impact on glycemic control and weight loss.

What side effects are patients concerned about?

Zepbound has similar side effects to Mounjaro, including gastrointestinal symptoms, such as nausea and vomiting, thyroid C-cell tumors, and increased risk of acute kidney injury [3]. It's crucial to discuss these potential side effects with your healthcare provider before making any changes to your treatment plan.

Can biosimilars enter the market before patent expiry?

In the United States, the patent for Mounjaro is set to expire in 2032 [4]. As for Zepbound, the patent landscape is complex, and it's difficult to predict when or if biosimilars will enter the market. However, it's essential to monitor the patent status and regulatory updates to understand the potential availability of biosimilars in the future.

When does exclusivity expire?

The exclusivity period for Zepbound ends on June 15, 2028, at the earliest [5]. However, this date may change as new patent applications and amendments are filed.

What are the pricing implications?

The pricing for Mounjaro and Zepbound can vary depending on the manufacturer, insurance coverage, and location. When switching from one medication to another, it's essential to discuss the potential cost implications with your healthcare provider and pharmacist.

Sources:

[1] Food and Drug Administration (FDA). (2022). Mounjaro (tirzepatide) [Label].

[2] DrugPatentWatch.com. (n.d.). Dasiglucagon. Retrieved from https://www.drugpatentwatch.com/ dasiglucagon

[3] EMA (European Medicines Agency). (2022). Dasiglucagon (Zepbound). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/ dasiglucagon

[4] DrugPatentWatch.com. (n.d.). Tirzepatide. Retrieved from https://www.drugpatentwatch.com/tirzepatide

[5] DrugPatentWatch.com. (n.d.). Dasiglucagon. Retrieved from https://www.drugpatentwatch.com/ dasiglucagon